<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082989</url>
  </required_header>
  <id_info>
    <org_study_id>110109</org_study_id>
    <nct_id>NCT03082989</nct_id>
  </id_info>
  <brief_title>Evolving Routine Standards in Intracoronary Physiology</brief_title>
  <acronym>ERIS</acronym>
  <official_title>Prospective Study Evaluating the Routine Standard Use of Fractional Flow Reserve and Disagreement With Guideline Recommendations: a Nationwide Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Ferrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Società Italiana di Cardiologia Invasiva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of Ferrara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Italy is the European country with the minor penetration of FFR as compared to the number of&#xD;
      percutaneous coronary intervention.&#xD;
&#xD;
      Accordingly, the Società Italiana di Cardiologia Invasiva (SICI-GISE) conceived and promoted&#xD;
      a prospective nationwide study to describe the patterns of the use of FFR in an unselected&#xD;
      real-world population and to to assess the reasons, on clinical decision making, driving&#xD;
      operators in the use or not of the FFR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fractional flow reserve (FFR) has been validated as a reliable surrogate for inducible&#xD;
      ischemia, supporting its use during invasive procedures for functional assessment of coronary&#xD;
      lesions. Landmark randomized trials have demonstrated that deferral of nonsignificant lesions&#xD;
      based on FFR is not only safe, but also that FFR-guided revascularization is associated with&#xD;
      a better clinical outcome up to 2 years, when compared with standard angiography.&#xD;
&#xD;
      In spite of the overwhelming evidence of its potential clinical and economic benefits and&#xD;
      strong guideline recommendation, the adoption of FFR in the real-world is perceived to vary&#xD;
      significantly. Reasons for this disparity are several, but most operators still do rely the&#xD;
      most on angiographic eye-balling to decide on the functional significance of coronary lesions&#xD;
      and the need for revascularization.&#xD;
&#xD;
      Italy is the European country with the minor penetration of FFR as compared to the number of&#xD;
      percutaneous coronary intervention.&#xD;
&#xD;
      Accordingly, the Società Italiana di Cardiologia Invasiva (SICI-GISE) conceived and promoted&#xD;
      a prospective nationwide study to describe the patterns of the use of FFR in an unselected&#xD;
      real-world population and to to assess the reasons, on clinical decision making, driving&#xD;
      operators in the use or not of the FFR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Actual">October 20, 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>agreement with current guidelines</measure>
    <time_frame>intra-procedure</time_frame>
    <description>percentage of patients receiving a FFR assessment in agreement with current guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>reasons leading to FFR disuse</measure>
    <time_frame>intra-procedure</time_frame>
    <description>description of the main reasons leading operator to prefer not assessment of coronary</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1858</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>fractional flow reserve performed</arm_group_label>
    <description>consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography where the operator decided to use fractional flow reserve to drive the revascularization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fractional flow reserve not performed</arm_group_label>
    <description>consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography and satisfying prespecified criteria where the operator decided to not use fractional flow reserve to drive the revascularization</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>fractional flow reserve performed</intervention_name>
    <description>assessing fractional flow reserve to drive revascularization</description>
    <arm_group_label>fractional flow reserve performed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fractional flow reserve not performed</intervention_name>
    <description>description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization</description>
    <arm_group_label>fractional flow reserve not performed</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive patients with ischemic heart disease and clinical indication to coronary artery&#xD;
        angiography&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        FRACTIONAL FLOW RESERVE PERFORMED GROUP&#xD;
&#xD;
          -  age &gt;18 years&#xD;
&#xD;
          -  written consent&#xD;
&#xD;
          -  assessment with FFR of at least one coronary lesion&#xD;
&#xD;
        FRACTIONAL FLOW RESERVE NOT PERFORMED GROUP&#xD;
&#xD;
          -  age &gt;18 years&#xD;
&#xD;
          -  written consent&#xD;
&#xD;
          -  absence of assessment with FFR of at least one coronary lesion&#xD;
&#xD;
             + at least one of the following criteria&#xD;
&#xD;
               1. stable coronary artery disease, absence of non-invasive stress test, evidence of&#xD;
                  coronary lesions between 50%-90% (visual estimation or quantitative coronary&#xD;
                  analysis)&#xD;
&#xD;
               2. stable coronary artery disease, presence of non-invasive stress test, evidence of&#xD;
                  coronary lesions between 50%-70% (visual estimation or quantitative coronary&#xD;
                  analysis)&#xD;
&#xD;
               3. acute coronary syndrome, culprit lesion not identifiable or coronary lesions&#xD;
                  different from the culprit between 50%-70% (visual estimation or quantitative&#xD;
                  coronary analysis)&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  written consent denied&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Luciano Rossi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas, Rozzano (MI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giulio Stefanino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas, Rozzano (MI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matteo Tebaldi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Ferrara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianluca Campo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Ferrara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Fineschi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Siena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Musumeci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Cuneo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Ferrara</name>
      <address>
        <city>Cona</city>
        <state>Ferrara</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Ferrara</investigator_affiliation>
    <investigator_full_name>Gianluca Campo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

